Newly Launched FHIR-Based Pharmacogenomics API Looks to Accelerate Precision Medicine | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Newly Launched FHIR-Based Pharmacogenomics API Looks to Accelerate Precision Medicine

August 18, 2016
by Rajiv Leventhal
| Reprints

A new application programming interface (API) that aims to aid health systems, labs and software developers to accelerate apps focused on precision medicine has been launched by Bellevue, Wash.-based Translational Software.

The company, known for solutions to support labs and providers adopting personalized medicine, developed the API using the Fast Healthcare Interoperability Resources (FHIR) specification, an open-sourced standard for exchanging healthcare information to ensure interoperability. Officials say the API can be used to query the company’s Knowledge-as-a-Service (KaaS) platform for drug-drug-gene intelligence to improve the prescription ordering process, alert clinicians to potential interactions and adverse drug events, and suggest medication alternatives.

The API is available for immediate use. Several leading organizations and independent software vendors are actively using the capability, including the Chan Soon-Shiong Institute of Molecular Research Institute, IT21 Solutions, First Vitals, RX Management, Sanford Health and Synergy Laboratories, the company announced.

“An important frontier of precision medicine is the use of clinical genomic data in routine patient care,” stated Gil Alterovitz, Ph.D., a Harvard Medical School professor in the Division of Medical Sciences, core faculty at the Computational Health Informatics Program in Boston Children’s Hospital and co-chair of HL7’s Clinical Genomics Work Group.

Initial efforts focused on developing FHIR apps that are integrated within the electronic health record (EHR) to provide clinicians with alerts and reports regarding drug efficacy, dosing and potential adverse reactions at the point of care. The API will have increasing relevance to a broad range of health information systems and initiatives over time as genetic testing becomes routine to guide clinical decision making, officials attested.

“One of the biggest impediments to wide-scale use of pharmacogenomics is the difficulty of integrating testing into the clinical workflow at the point where prescribing decisions are being made,” stated Don Rule, CEO, Translational Software. “We see a standardized API as a powerful means of simplifying this integration, and are grateful for the opportunity to collaborate with our partners to flesh out the standard.”

Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More



Boston Children's Accelerates Data-Driven Approach to Clinical Research

In an effort to bring a more data-driven approach to clinical research, Boston Children’s Hospital has joined the TriNetX global health research network.

Paper Records, Films Most Common Type of Healthcare Data Breach, Study Finds

Despite the high level of hospital adoption of electronic health records and federal incentives to do so, paper and films were the most frequent location of breached data in hospitals, according to a recent study.

AHA Appoints Senior Advisor for Cybersecurity and Risk

The American Hospital Association (AHA) has announced that John Riggi has joined the association as senior advisor for cybersecurity and risk.

Report: Healthcare Accounted for 45% of All Ransomware Attacks in 2017

Healthcare fell victim to more ransomware attacks than any other industry in 2017, according to a new report from global cybersecurity insurance company Beazley.

Study: Use of EHRs Does Not Reduce Administrative Costs

A recent study by Duke University and Harvard Business School researchers found that costs for processing a single bill ranged from $20 for a primary care visit to $215 for an inpatient surgical procedure, or up to 25 percent of revenue.

Kibbe to Step Down as CEO of DirectTrust

David Kibbe, M.D., M.B.A., announced he would step down as president and CEO of DirectTrust at the end of the year.